The Butyrophilin 1A1 antibody targets the BTN1A1 protein, a member of the butyrophilin family. Structurally, the antibody is designed as a full-length IgG1 molecule with high specificity for the extracellular domain of BTN1A1. Its mechanism involves blocking the protein's ability to suppress T-cell activation, thereby enhancing anti-tumor immune responses.
| Characteristic | Detail |
|---|---|
| Target | Butyrophilin 1A1 (BTN1A1) |
| Antibody Type | Monoclonal IgG1 |
| Binding Site | Extracellular domain of BTN1A1 (Ala27-Arg242) |
| Species Origin | Humanized or chimeric (under development) |
Recent studies highlight the antibody's therapeutic potential:
A preclinical study in tumor-bearing mice demonstrated:
Tumor Growth Suppression: Antibody-mediated blockade of BTN1A1 inhibited tumor growth by 60% compared to controls .
T-Cell Activation: BTN1A1 suppression restored CD4+ and CD8+ T-cell infiltration into the tumor microenvironment .
Mutual Exclusivity with PD-L1: BTN1A1 expression inversely correlated with PD-L1 levels, suggesting it as a complementary target for PD-1/PD-L1-refractory cancers .
| Outcome | Measurement | Result |
|---|---|---|
| Tumor Volume Reduction | Tumor weight (mg) | 40% reduction |
| T-Cell Infiltration | CD8+ T-cell density | 3.2-fold increase |
| PD-L1 Expression | RT-qPCR analysis | Negative correlation (r = -0.8) |
The Butyrophilin 1A1 antibody is currently in early-stage development for:
Solid Tumors: Studies focus on cancers with low PD-L1 expression, including melanoma and colorectal carcinoma .
Immune Evasion: Its ability to counteract T-cell suppression in PD-1/PD-L1-resistant tumors positions it as a next-generation immunotherapy .
Preclinical: Completed efficacy testing in syngeneic mouse models .
Clinical: Phase I trials expected to commence in 2026, targeting refractory cancers .
| Feature | PD-1/PD-L1 | BTN1A1 |
|---|---|---|
| Expression Pattern | Variable across tumor types | Mutually exclusive with PD-L1 |
| Tumor Response | Limited to PD-L1+ tumors | Effective in PD-L1 negative |
| Resistance Mechanism | Adaptive upregulation | Intrinsic suppression |
Antigen Heterogeneity: Variable BTN1A1 expression across tumor types necessitates biomarker-driven trials .
Combination Therapies: Synergy with bispecific antibodies (e.g., dual targeting of CD19 and CD3) is under exploration .
Toxicity Profiling: Preclinical data suggest minimal off-target effects, but human trials will validate safety .
KEGG: spo:SPAC27D7.12c
STRING: 4896.SPAC27D7.12c.1
BUT1 (also known as mug107 or SPAC27D7.12c) is a Uba3-binding protein involved in the neddylation pathway in fission yeast . It functions as a meiotically up-regulated gene product that appears to be regulated by the transcription factor Phx1, which contributes to long-term survival and stress tolerance . While specific molecular mechanisms remain under investigation, BUT1 likely plays a role in protein modification through the neddylation process, which is essential for various cellular functions including cell cycle progression and stress response.
The protein has been identified as part of studies investigating gene expression changes during stationary phase and stress conditions. Research indicates that BUT1/mug107 expression decreases in Δphx1 mutants, suggesting its regulation by the Phx1 transcription factor that contributes to long-term survival mechanisms .
Currently, polyclonal antibodies against BUT1 from Schizosaccharomyces pombe are commercially available for research purposes. These include:
Rabbit anti-Schizosaccharomyces pombe BUT1 Polyclonal Antibody (specificity for strain 972/ATCC 24843)
Preparations in different quantities (standard 2ml/0.1ml formats and larger 10mg quantities)
These antibodies have been validated for applications including:
While monoclonal antibodies might provide higher specificity for certain applications, the literature search results do not indicate commercially available monoclonal BUT1 antibodies at this time.
When designing experiments to study BUT1 involvement in cell cycle regulation, consider implementing synchronized cell cultures using the temperature-sensitive cdc25-22 allele method. This approach allows collection of sufficient quantities of synchronized cells for downstream applications like ChIP .
Recommended experimental approach:
Cell synchronization protocol:
Sample processing for BUT1 detection:
Fix cells at defined time points after synchronization release
Process for antibody-based detection methods (immunofluorescence or Western blotting)
Include appropriate controls (see section 2.4)
Data collection parameters:
Monitor BUT1 localization/abundance throughout cell cycle phases
Correlate with cell cycle markers and cellular structures
Quantify changes in protein levels or localization patterns
This approach will allow you to determine if BUT1 exhibits cell cycle-dependent regulation similar to other proteins involved in critical cellular processes like chromosome segregation in fission yeast .
Western blotting with BUT1 antibody requires careful optimization to ensure specificity and sensitivity. Based on general principles for fission yeast proteins and the specific characteristics of BUT1:
Recommended Western blot protocol:
Sample preparation:
Gel electrophoresis parameters:
Use 10-12% SDS-PAGE for optimal resolution (BUT1 is approximately 55kDa)
Load 20-40 μg total protein per lane
Include positive control (recombinant BUT1 if available)
Transfer and antibody incubation:
Transfer to PVDF membrane (0.45 μm pore size)
Block with 5% non-fat milk in TBST for 1 hour at room temperature
Incubate with BUT1 antibody at 1:1000 dilution overnight at 4°C
Wash thoroughly with TBST (4 × 5 minutes)
Incubate with appropriate secondary antibody (anti-rabbit IgG-HRP) at 1:5000 dilution
Detection and troubleshooting:
Use enhanced chemiluminescence for detection
Expected band size: ~55 kDa (verify against protein marker)
If background is high, increase blocking time or adjust antibody concentration
Remember that protein extraction from fission yeast can be challenging due to the rigid cell wall. Efficient cell lysis is critical for successful protein detection.
Immunofluorescence with fission yeast requires special considerations for cell wall digestion and fixation. For BUT1 detection:
Optimized immunofluorescence protocol:
Cell preparation:
Cell wall digestion:
Treat with zymolyase (1 mg/mL) in PEMS buffer for 30-60 minutes at 37°C
Monitor digestion microscopically
Permeabilize with 1% Triton X-100 for 5 minutes
Antibody incubation:
Block with 1% BSA in PBS for 1 hour at room temperature
Incubate with BUT1 primary antibody (1:100-1:500 dilution) overnight at 4°C
Wash 3× with PBS-T
Incubate with fluorescently-labeled secondary antibody (1:500) for 1 hour
Counterstain with DAPI (1 μg/mL) to visualize nuclei
Imaging considerations:
Use confocal microscopy for optimal resolution
Capture Z-stacks to properly assess localization patterns
Include appropriate controls (see section 2.4)
For accurate localization studies, consider co-staining with markers for specific cellular compartments (nucleus, centromeres, cell wall) to determine BUT1's precise subcellular distribution.
Proper controls are essential for interpreting antibody-based experiments accurately. When working with BUT1 antibody, include the following controls:
Essential controls for BUT1 antibody experiments:
Specificity controls:
Technical controls:
Secondary antibody only: Omit primary antibody to detect non-specific binding
Loading control: Use antibody against housekeeping protein (e.g., tubulin, actin)
Positive control: If studying induced conditions, include samples where BUT1 is known to be expressed
Additional controls for immunofluorescence:
| Control Type | Purpose | Implementation |
|---|---|---|
| Negative Control | Validate specificity | Use Δbut1 strain extract |
| Blocking Peptide | Confirm antibody specificity | Pre-incubate antibody with antigen |
| Isotype Control | Detect non-specific binding | Use matched concentration of non-specific IgG |
| Secondary Only | Detect secondary antibody background | Omit primary antibody |
| Loading Control | Normalize protein amounts | Probe for housekeeping protein |
These controls will help distinguish genuine BUT1 signal from experimental artifacts and non-specific binding.
ChIP experiments using BUT1 antibody can help determine if BUT1 associates with chromatin and specific DNA regions. This is particularly relevant given the potential role of BUT1 in meiosis and stress response through transcriptional regulation pathways.
ChIP protocol for BUT1:
Sample preparation:
Chromatin preparation:
Lyse cells with glass beads in lysis buffer containing protease inhibitors
Sonicate to generate DNA fragments of 200-500 bp
Verify fragmentation by agarose gel electrophoresis
Pre-clear chromatin with Protein A/G beads
Immunoprecipitation:
Incubate chromatin with BUT1 antibody (5-10 μg) overnight at 4°C
Add Protein A/G beads and incubate for 2-3 hours
Wash beads extensively with increasing salt concentrations
Elute protein-DNA complexes and reverse cross-links
Analysis methods:
Given the potential link between BUT1 and transcriptional regulation during stress and meiosis, focus ChIP analysis on promoter regions of genes involved in these processes to identify potential regulatory relationships.
Proximity ligation assay (PLA) is an advanced technique to visualize protein-protein interactions in situ with high sensitivity. For BUT1 interaction studies:
PLA protocol optimization:
Cell preparation:
Follow standard immunofluorescence protocol for fission yeast
Fix and permeabilize cells as described in section 2.3
Block with Duolink blocking solution
Primary antibody incubation:
Incubate with BUT1 antibody (1:100-1:200)
Co-incubate with antibody against potential interaction partner
Ensure antibodies are from different host species
PLA-specific steps:
Add PLA probes against host species of both primary antibodies
Perform ligation and amplification according to manufacturer's protocol
Counterstain nuclei with DAPI
Analysis considerations:
Quantify PLA signals per cell
Compare signal intensity across different conditions
Include appropriate negative controls (single antibody, non-interacting protein)
Based on BUT1's function in the neddylation pathway, potential interaction partners to investigate include:
Components of the neddylation machinery
BUT1 may play a role in stress response pathways, as it's regulated by Phx1, a transcription factor involved in long-term survival and stress tolerance . To investigate BUT1 expression changes:
Stress response experimental design:
Stress induction conditions:
Sample collection:
Harvest cells at multiple time points post-stress
Include pre-stress baseline samples
Process for Western blot or immunofluorescence
Quantitative analysis:
Measure BUT1 protein levels by Western blot densitometry
Normalize to loading control (actin or tubulin)
Calculate fold change relative to unstressed condition
Correlation with phenotypic data:
Monitor cell viability under stress conditions
Compare wild-type and Δphx1 strains
Assess potential correlation between BUT1 levels and survival rates
This approach will help establish if BUT1 is part of the cellular stress response system and whether its regulation is critical for adaptation to adverse conditions.
When working with BUT1 antibody, several specificity issues may arise:
Common specificity issues and solutions:
High background in Western blots:
Issue: Non-specific binding to multiple proteins
Solution: Increase blocking time (2-3 hours), use 5% BSA instead of milk, increase wash stringency, titrate antibody concentration
Multiple bands in Western blot:
Issue: Cross-reactivity or post-translational modifications
Solution: Verify with knockout control, use blocking peptide, optimize extraction conditions to prevent proteolysis
Weak or no signal:
Issue: Insufficient protein extraction or antibody concentration
Solution: Optimize extraction method for cell wall proteins, increase antibody concentration, extend incubation time
Inconsistent results between experiments:
Issue: Variability in experimental conditions
Solution: Standardize growth conditions, use fresh antibody aliquots, maintain consistent incubation parameters
When troubleshooting, always return to fundamental controls and consider testing multiple antibody lots if available. For fission yeast proteins, extraction efficiency is often a critical factor in successful detection.
Various experimental conditions can significantly impact BUT1 antibody performance:
Critical parameters affecting antibody performance:
| Parameter | Western Blot | Immunofluorescence | ChIP |
|---|---|---|---|
| Fixation | N/A | Critical (3.7% formaldehyde optimal) | Critical (1% formaldehyde, 15 min) |
| Cell wall digestion | Not applicable | Essential (use zymolyase) | Not required (sonication breaks cells) |
| Antibody dilution | 1:1000-1:2000 | 1:100-1:500 | 5-10 μg per reaction |
| Incubation time | Overnight at 4°C | Overnight at 4°C | Overnight at 4°C |
| Buffer composition | TBS-T with 5% milk/BSA | PBS with 1% BSA | IP buffer with protease inhibitors |
| Detection method | HRP-conjugated secondary | Fluorescent secondary | qPCR or sequencing |
Optimization recommendations:
For Western blotting, test multiple extraction methods if signal is weak
For immunofluorescence, optimize cell wall digestion time carefully
For ChIP, test different sonication conditions to achieve optimal DNA fragmentation
Each application requires specific optimization of these parameters for successful BUT1 detection.
Antibody lot-to-lot variation can significantly impact experimental results. To validate new lots:
Antibody validation protocol:
Initial quality control:
Check appearance (no visible precipitates)
Verify concentration (Bradford assay or A280 measurement)
Confirm host species and clonality match specifications
Performance comparison:
Run side-by-side Western blots with old and new lots
Use identical samples and conditions
Quantify band intensity and background
Calculate signal-to-noise ratio for comparison
Titration analysis:
Test multiple dilutions (e.g., 1:500, 1:1000, 1:2000)
Determine optimal working concentration
Compare with previous lot's optimal concentration
Specificity validation:
Confirm absence of signal in knockout/negative control
Verify expected molecular weight of detected protein
Test blocking peptide competition if available
Document all validation results for future reference, including optimal working dilutions for each application and lot number.
Contradictory results with BUT1 antibody across different experimental systems require systematic troubleshooting:
Approach to resolving contradictory results:
Verify antibody specificity:
Confirm signal absence in knockout/negative controls
Perform blocking peptide competition
Test multiple antibody dilutions to optimize signal-to-noise ratio
Evaluate experimental differences:
Consider biological variables:
Resolution strategies:
Use multiple detection methods (e.g., both Western blot and immunofluorescence)
Implement more controls to identify variables affecting results
Quantify results with appropriate statistical analysis
When contradictory results persist, consider that they may reflect genuine biological complexity rather than technical issues.
Analyzing BUT1 localization can provide valuable insights into its function:
Interpretation framework for localization data:
Nuclear localization:
Cytoplasmic localization:
Dynamic localization changes:
Co-localization analysis:
Correlate localization data with functional studies (gene knockouts, point mutations) to establish causal relationships between localization and function.
A multi-dimensional approach yields the most comprehensive understanding of BUT1 function:
Integration framework:
Combine protein-level data with transcriptomics:
Compare BUT1 protein levels (antibody detection) with mRNA expression
Analyze correlation between protein abundance and transcript levels under various conditions
Identify potential post-transcriptional regulation mechanisms
Correlate with genetic studies:
Compare antibody-detected phenotypes with knockout phenotypes
Use antibody to assess protein levels in point mutants
Analyze suppressor or synthetic genetic interactions
Link molecular data to physiological outcomes:
Data visualization and analysis:
Create integrated heatmaps showing protein levels, localization, and phenotypic data
Perform statistical analysis to identify significant correlations
Develop predictive models for BUT1 function based on integrated datasets
This multi-layered approach can help distinguish correlation from causation and place BUT1 within its biological context more accurately.